pharmadog
News
when
  • Latest
  • Archive
by source
  • All Sources
  • Sources Page
Jobs
department
  • Clinical
  • Regulatory
  • Medical Affairs
  • Commercial
  • R&D / Discovery
  • Biostatistics / Data
  • Manufacturing / CMC
  • Market Access
therapeutic area
  • Oncology
  • Immunology
  • Neuroscience
  • Cardiovascular
  • Metabolic
  • Rare Disease
  • Infectious Disease
location & type
  • Remote Only
  • US Only
  • California
  • Massachusetts
  • Internships
  • Phase 3 Roles
  • All Jobs →
Sign InSubscribe
pharmadog

fetch the data · sniff the signal

Discover
  • Jobs
  • News
Hubs
  • Topics
  • Patent cliff
  • Publications
Tools
  • Compare
  • Search
  • Bookmarks
Trust
  • About
  • Sources
  • Contact
Legal
  • Privacy
  • Terms
  • Pricing

© 2026 pharmadog.xyz

made by humans and a good dog

  • home
  • jobs
  • news
  • search
  1. pharmadog
  2. ›drugs
  3. ›Latisse
drug
save

Lumigan

Marketedupdated 3mo ago
by $ABBV AbbVie Inc.
Approved
community read0 votes

🐶 often sniffed alongside

top 5
  • drugBIMATOPROST3 co-mentions · 3 sources
  • drugbimatoprost CR3 co-mentions · 3 sources
  • drugbimatoprost SR3 co-mentions · 3 sources
  • tagApproval2 co-mentions · 1 sources
  • tagRecall2 co-mentions · 2 sources

Small molecule drug with a maximum clinical stage of Approval (across all indications), with 6 approved and 8 investigational indications.

all catalysts(1)

approval · 1
Sep 22, 2025
approval
$AMRX18.15+5.10%
11mo ago
BIMATOPROST — FDA approval
Lumigan
→

Trials studying Lumigan

  • phase3Long-term Safety and Efficacy Extension Trial of Bimatoprost SRcompletedn=455
  • phase2AGN-193408 SR in the Treatment of Open-angle Glaucoma or Ocular Hypertensionrecruitingn=96
  • phase4Biomarkers of Ocular Surface Damage in the Setting of Topical Ocular Hypotensive Medication Userecruitingn=20
  • phase3Evaluation of the Safety and Efficacy of the Bimatoprost Implant System Used in Combination With the SpyGlass IOL Compared to Timolol Ophthalmic Solution (Rhine)recruitingn=400
  • phase3Evaluation of the Safety and Efficacy of the Bimatoprost Implant System Used in Combination With the SpyGlass IOL Compared to Timolol Ophthalmic Solution (Rhone)recruitingn=400
  • N/AEvaluation of the Safety and Effectiveness of the Bimatoprost Implant System / IOL Combination in Patients With Ocular Hypertension or Mild to Moderate Open-angle Glaucomacompletedn=24
  • phase2Evaluation of the Bimatoprost Implant System Used in Combination With the SpyGlass Intraocular Lens Compared to Timolol Ophthalmic Solutionactive not recruitingn=201
  • phase3Evaluation of the Duration of Effect of Bimatoprost SR in Participants With Open-Angle Glaucoma or Ocular Hypertensioncompletedn=515
more trials →

Patent cliff

source: FDA Orange Book
first barrier falls
Dec 19, 2026
126 days

Earliest of all listed patents + FDA exclusivities. Generic / biosimilar entry typically only becomes possible AFTER both patent and exclusivity barriers expire.

patents (9)

  • Jun 8, 2036formulationUS 10314780
  • Oct 31, 2034formulationUS 9492316
  • Oct 31, 2034method-of-use (U-2759)US 9980974
  • Jul 15, 2031compositionUS 86291854.9y
  • Apr 24, 2029formulationUS 77993362.7y
  • Jun 13, 2027compositionUS 7851504302d
  • Apr 7, 2027method-of-use (U-2759)US 8206737235d
  • Dec 19, 2026formulationUS 10441543126d
  • Dec 19, 2026formulationUS 9149428126d

FDA exclusivities (1)

  • Sep 9, 2028NDFNew Dosage Form (3y)2.1y

News(0)

no news has mentioned this drug yet

brand
Latisse
generic
bimatoprost
MOA
Prostanoid FP receptor agonist
indication
Ocular Hypertension
phase
marketed
Data sources
openFDA · ClinicalTrials.gov
last refreshed 22m ago
Found something off?
🐶 something off?

Report a data issue

Tell Bork what looks wrong — wrong sponsor, stale phase, mislinked ticker, anything. We’ll triage and fix.

comments(0)

5-min edit window · permanent after that
sign in to leave a comment · permanent archive after 5 minutes
no comments yet — first sniff?